Jim Tananbaum, the CEO of Foresite Capital, has demonstrated his superiority in the business world by appearing in the 2017 Forbes’ Midas List of Top 100 Tech Investors. The visionary leader was ranked position 52. This is his third consecutive year to be recognized by the prestigious Forbes Magazine. This achievement reflects his continuous dedication to success at Foresite Capital, a healthcare investment company. The Forbes’s Midas List honors venture capitalists who exhibit excellent performance in top tech companies of tomorrow and those who create unique value for their investors. Forbes partners with TrueBridge Capital Partners to collect data from various public sources before calculating and determining the ideal ranks of the venture capitalist’s investment. The investments include the size of private valuation, deal value and other major metrics against their peers. You can visit Ideamensch to know more.
Dr. Jim Tananbaum has rendered his services in the healthcare industry for many years. He primarily focuses on entrepreneurship and investment. Jim is the founder of Foresite Capital, where he also serves as the managing director. Here, Jim Tananbaum builds franchise healthcare companies through strategic, financial and operational opportunities. He oversees the company’s investment strategy and organizational structure. Foresite Capital invests in biotechnology, diagnostics, genomics, medical devices and healthcare services. His involvement in the business has seen him found and fund various companies. In 2001, Jim Tananbaum co-founded Prospect Venture Partners (PVP) where he served as the managing director for 9 years. PVP, a $1 billion healthcare venture capital group, specialized in series A financings.
In addition, Dr. Tananbaum co-founded Theravance (THRX), where he served as the CEO for three years. Previously, Jim was a Partner at Sierra Ventures where he led investments in Healtheon, Amerigroup, Novamed and Careselect. Tananbaum is also the co-founder and CEO of Geltex Pharmaceuticals, where he helped to create two non-systematic drugs, Renzela and Cholestagel. The company was later sold at $1.6 billion. Presently, he serves as the president of the Advisory Board of Yale University and Advisor at Harvard MIT HST Program. Notably, the doctor is an alumnus of the celebrated Harvard Medical School where he graduated with his MD and a master’s of science degree. He is highly skilled in deal sourcing, mergers, IPO, private equity, due diligence and corporate development. Check out Forbes for more details.
Check out his website officialjimtananbaum.com